Interactions between curcumin and human salt-induced kinase 3 elucidated from computational tools and experimental methods

• Published in: Frontiers in pharmacology Vol. 14; p. 1116098
• Main Authors: Shi, Mingsong, Zhou, Yan, Wei, Haoche, Zhang, Xinyu, Du, Meng, Zhou, Yanting, Yin, Yuan, Li, Xinghui, Tang, Xinyi, Sun, Liang, Xu, Dingguo, Li, Xiaoan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13.04.2023
• Subjects: binding free energy; binding model; curcumin; molecular docking; molecular dynamics simulation; Pharmacology; salt-induced kinase; binding model; molecular docking; binding free energy; salt-induced kinase; molecular dynamics simulation; curcumin
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2023.1116098

Natural products are widely used for treating mitochondrial dysfunction-related diseases and cancers. Curcumin, a well-known natural product, can be potentially used to treat cancer. Human salt-induced kinase 3 (SIK3) is one of the target proteins for curcumin. However, the interactions between curcumin and human SIK3 have not yet been investigated in detail. In this study, we studied the binding models for the interactions between curcumin and human SIK3 using computational tools such as homology modeling, molecular docking, molecular dynamics simulations, and binding free energy calculations. The open activity loop conformation of SIK3 with the ketoenol form of curcumin was the optimal binding model. The I72, V80, A93, Y144, A145, and L195 residues played a key role for curcumin binding with human SIK3. The interactions between curcumin and human SIK3 were also investigated using the kinase assay. Moreover, curcumin exhibited an IC (half-maximal inhibitory concentration) value of 131 nM, and it showed significant antiproliferative activities of 9.62 ± 0.33 µM and 72.37 ± 0.37 µM against the MCF-7 and MDA-MB-23 cell lines, respectively. This study provides detailed information on the binding of curcumin with human SIK3 and may facilitate the design of novel salt-inducible kinases inhibitors.